AR061170A1 - Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) - Google Patents
Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)Info
- Publication number
- AR061170A1 AR061170A1 ARP070102388A ARP070102388A AR061170A1 AR 061170 A1 AR061170 A1 AR 061170A1 AR P070102388 A ARP070102388 A AR P070102388A AR P070102388 A ARP070102388 A AR P070102388A AR 061170 A1 AR061170 A1 AR 061170A1
- Authority
- AR
- Argentina
- Prior art keywords
- growth factor
- fch
- proteins
- hepatocite
- hgf
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 abstract 3
- 108091008324 binding proteins Proteins 0.000 abstract 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81071406P | 2006-06-02 | 2006-06-02 | |
| US86046106P | 2006-11-21 | 2006-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061170A1 true AR061170A1 (es) | 2008-08-06 |
Family
ID=38802082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102388A AR061170A1 (es) | 2006-06-02 | 2007-06-01 | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US7659378B2 (enExample) |
| EP (2) | EP2380908A1 (enExample) |
| JP (2) | JP4560582B2 (enExample) |
| KR (1) | KR101196184B1 (enExample) |
| AR (1) | AR061170A1 (enExample) |
| AT (1) | ATE533787T1 (enExample) |
| AU (1) | AU2007254853B2 (enExample) |
| BR (1) | BRPI0712223A2 (enExample) |
| CA (1) | CA2654019A1 (enExample) |
| ES (1) | ES2378097T3 (enExample) |
| IL (2) | IL195038A0 (enExample) |
| MX (1) | MX2008015138A (enExample) |
| NO (1) | NO20085422L (enExample) |
| NZ (1) | NZ573819A (enExample) |
| WO (1) | WO2007143098A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659378B2 (en) * | 2006-06-02 | 2010-02-09 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| CA2654025C (en) * | 2006-06-02 | 2016-08-02 | Xoma Technology Ltd. | Hepatocyte growth factor (hgf) binding proteins |
| HUE027154T2 (en) | 2007-07-02 | 2016-08-29 | Oncomed Pharm Inc | Preparations and procedures for the treatment and diagnosis of cancer |
| US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| US8846036B2 (en) * | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| AU2009241589B2 (en) * | 2008-04-29 | 2013-10-10 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CA2725873C (en) | 2008-05-29 | 2018-05-01 | Galaxy Biotech, Llc | Monoclonal antibodies to basic fibroblast growth factor |
| EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| NZ589434A (en) * | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8187601B2 (en) * | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| HUE028589T2 (en) * | 2008-07-10 | 2016-12-28 | Toray Industries | Pharmaceutical preparation for the treatment and prevention of cancer |
| US8101723B2 (en) | 2008-11-07 | 2012-01-24 | Galaxy Biotech, Llc | Monoclonal antibodies to fibroblast growth factor receptor 2 |
| JP2012508563A (ja) * | 2008-11-12 | 2012-04-12 | シェーリング コーポレイション | 抗ＩＧＦ１Ｒ発現の増強のためのβＧｌ−ＩＧＧイントロン |
| WO2010119991A2 (en) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| BR112012004710A2 (pt) * | 2009-09-01 | 2016-08-16 | Abbott Lab | imunoglobulinas de domínio variável duplo e uso das mesmas |
| PH12012500691A1 (en) | 2009-10-15 | 2012-11-12 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| AR082461A1 (es) | 2010-08-03 | 2012-12-12 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX2013002270A (es) | 2010-08-26 | 2013-05-14 | Abbvie Inc | Inmonoglubinas de dominio variable doble y usos de las mismas. |
| US20130236467A1 (en) | 2010-11-24 | 2013-09-12 | Jeremy Griggs | Multispecific antigen binding proteins targeting hgf |
| EP2731625B1 (en) | 2011-07-15 | 2018-04-18 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| WO2013078223A1 (en) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| AU2013289990B2 (en) | 2012-07-13 | 2018-06-14 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
| CA2890263C (en) | 2012-11-01 | 2020-03-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
| EP2964673A4 (en) * | 2013-03-14 | 2017-02-22 | Alder Biopharmaceuticals, Inc. | Antibodies to hgf and compositions containing |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| WO2015031578A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Hgf assay |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| EP3180027A4 (en) * | 2014-08-15 | 2018-01-10 | Oncomed Pharmaceuticals, Inc. | Rspo1 binding agents and uses thereof |
| JP2017528523A (ja) | 2014-09-16 | 2017-09-28 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 線維性疾患の治療 |
| ES2822228T3 (es) * | 2014-10-24 | 2021-04-29 | Univ Leland Stanford Junior | Composiciones y métodos para inducir la fagocitosis de células positivas de clase I de CMH y contrarrestar la resistencia a anti-CD47/SIRPA |
| US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| JP7366388B2 (ja) | 2016-03-28 | 2023-10-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗Ｒｙｋ抗体およびその使用方法 |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| EP3634486A4 (en) | 2017-06-05 | 2021-03-31 | Janssen Biotech, Inc. | GENETICALLY PRODUCED MULTISPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS OF THE CH2-CH3 REGION |
| WO2018232188A1 (en) * | 2017-06-15 | 2018-12-20 | Memorial Sloan Kettering Cancer Center | Anti-l1-cam antibodies and uses thereof |
| IL319835A (en) | 2017-12-06 | 2025-05-01 | Avidity Biosciences Inc | Compositions and methods for treating muscular dystrophy and myotonic dystrophy |
| US11155638B2 (en) | 2018-05-08 | 2021-10-26 | Rhode Island Hospital | Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications |
| CA3133633A1 (en) * | 2019-03-20 | 2020-09-24 | Javelin Oncology, Inc. | Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising |
| CA3148713A1 (en) | 2019-08-12 | 2021-02-18 | Interna Technologies B.V. | New treatments involving mirna-193a |
| US20230136088A1 (en) | 2020-02-28 | 2023-05-04 | Interna Technologies B.V. | miRNA-193a for Promoting Immunogenic Cell Death |
| MX2022011880A (es) | 2020-03-27 | 2022-10-20 | Avidity Biosciences Inc | Composiciones y metodos para tratar distrofia muscular. |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| EP1514934B1 (en) | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| US7459536B1 (en) | 1999-11-09 | 2008-12-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | HGF-SF monoclonal antibody combinations |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| US8609090B2 (en) | 2003-07-18 | 2013-12-17 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
| KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| KR20080026562A (ko) | 2005-06-02 | 2008-03-25 | 갤럭시 바이오테크, 엘엘씨 | 항체를 이용한 뇌종양 치료 방법 |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| US7659378B2 (en) * | 2006-06-02 | 2010-02-09 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| CA2654025C (en) | 2006-06-02 | 2016-08-02 | Xoma Technology Ltd. | Hepatocyte growth factor (hgf) binding proteins |
| KR100829972B1 (ko) | 2006-07-14 | 2008-05-16 | 재단법인서울대학교산학협력재단 | 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법 |
-
2007
- 2007-06-01 US US11/757,094 patent/US7659378B2/en active Active
- 2007-06-01 NZ NZ573819A patent/NZ573819A/en not_active IP Right Cessation
- 2007-06-01 MX MX2008015138A patent/MX2008015138A/es active IP Right Grant
- 2007-06-01 ES ES07795607T patent/ES2378097T3/es active Active
- 2007-06-01 KR KR1020087032082A patent/KR101196184B1/ko not_active Expired - Fee Related
- 2007-06-01 AT AT07795607T patent/ATE533787T1/de active
- 2007-06-01 AU AU2007254853A patent/AU2007254853B2/en not_active Ceased
- 2007-06-01 AR ARP070102388A patent/AR061170A1/es not_active Application Discontinuation
- 2007-06-01 EP EP11159440A patent/EP2380908A1/en not_active Withdrawn
- 2007-06-01 EP EP07795607A patent/EP2029627B1/en not_active Not-in-force
- 2007-06-01 JP JP2009513297A patent/JP4560582B2/ja not_active Expired - Fee Related
- 2007-06-01 BR BRPI0712223-3A patent/BRPI0712223A2/pt not_active IP Right Cessation
- 2007-06-01 CA CA002654019A patent/CA2654019A1/en not_active Abandoned
- 2007-06-01 WO PCT/US2007/012950 patent/WO2007143098A2/en not_active Ceased
-
2008
- 2008-11-02 IL IL195038A patent/IL195038A0/en unknown
- 2008-12-30 NO NO20085422A patent/NO20085422L/no not_active Application Discontinuation
-
2009
- 2009-12-07 US US12/632,758 patent/US7935502B2/en not_active Expired - Fee Related
-
2010
- 2010-07-26 JP JP2010167648A patent/JP5528246B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-18 US US13/051,474 patent/US8268315B2/en not_active Expired - Fee Related
-
2012
- 2012-05-08 IL IL219655A patent/IL219655A0/en unknown
- 2012-08-20 US US13/589,652 patent/US8575318B2/en not_active Expired - Fee Related
-
2013
- 2013-09-27 US US14/039,912 patent/US20140178934A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061170A1 (es) | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) | |
| AR061171A1 (es) | Proteinas de union al factor de crecimiento de hepatocitos (fch) | |
| AR064087A1 (es) | Compuestos | |
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| CR11795A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| EA201591754A1 (ru) | Человеческие антитела к na1.7 | |
| MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| ECSP12011922A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CO6541597A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| DOP2012000122A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UY33826A (es) | Proteínas de unión con dominios trivariables y sus usos | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| UY32808A (es) | Inmunoglobulinas como dominio variable dual y usos de las mismas | |
| ECSP13012648A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| DOP2013000047A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UY33707A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| DOP2013000025A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CR20130074A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| ECSP13012402A (es) | Inmunoglobulinas con dominio variable dual y su uso | |
| BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
| MX353964B (es) | Agentes terapeuticos y usos de los mismos. | |
| MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
| BRPI0712607A8 (pt) | métodos de tratamento de acidente vascular cerebral | |
| CO6541599A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |